<DOC>
	<DOCNO>NCT00002120</DOCNO>
	<brief_summary>To evaluate safety combination trimetrexate glucuronate ( TMTX ) dapsone leucovorin protection versus trimethoprim/sulfamethoxazole ( TMP/SMX ) patient AIDS moderately severe Pneumocystis carinii pneumonia ( PCP ) . To determine pharmacokinetic parameter TMTX , leucovorin , dapsone TMP/SMX give patient AIDS moderately severe PCP .</brief_summary>
	<brief_title>Randomized Phase I Study Trimetrexate Glucuronate ( TMTX ) With Leucovorin ( LCV ) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole ( TMP/SMX ) Treatment Moderately Severe Episodes Pneumocystis Carinii Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Empiric therapy opportunistic pulmonary infection ( TB fungi ) first 72 hour study enrollment ONLY , presence suspect pathogen confidently exclude . Patients must : AIDS . Confirmed diagnosis PCP . Alveolararterial difference dissolve oxygen &gt; = 35 mm Hg &lt; 55 mm Hg room air . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Severe renal hepatic dysfunction . Serious lifethreatening intolerance TMP/SMX , TMTX , dapsone . Concurrent pneumothorax . Active pulmonary tuberculosis inadequately treat opportunistic pulmonary infection ( e.g. , Cryptococcus neoforms , CMV ) . NOTE : Identification Mycobacterium avium CMV sputum BAL fluid exclude , since organism may present without cause disease . Pulmonary Kaposi 's sarcoma . Active opportunistic infection malignancy require induction therapy bone marrow suppressive drug ( e.g. , ganciclovir ) hepatotoxic drug ( e.g. , chemotherapy ) . Unable arterial blood gas room air obtain baseline . Unwilling undergo bronchoscopy , sputum induction reveal Pneumocystis carinii . Suspected malabsorption ( e.g. , ileus severe diarrhea &gt; 6 stools/day ) . Known absence G6PD activity . Large volume ( 1.0 1.5 liter ) intravenous fluid ( 5 percent water ) per 24 hour medically inadvisable . Unwilling comply study design . Concurrent Medication : Excluded : Induction therapy bone marrow suppressive drug ( e.g. , ganciclovir ) hepatotoxic drug ( e.g. , chemotherapy ) . AZT , ddI , ddC , d4T , antiretroviral therapy . Patients follow prior condition exclude : Prior history serious lifethreatening intolerance TMP/SMX . ( NOTE : Patients less severe reaction may include discretion investigator primary care provider . ) Prior Medication : Excluded : More 24 hour systemic antiPCP therapy within 2 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Trimetrexate</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Dapsone</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>